← Back to headlines
Emergent BioSolutions Stock Plummets on Weak 2026 Revenue Guidance and Q4 Results
Emergent BioSolutions' stock experienced a significant drop following the release of its fourth-quarter results and a weak revenue guidance for 2026.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
